Dissecting the Decision: Investigators Discuss Available and Emerging Data on the Use of PARP Inhibitors in Ovarian Cancer and Other Novel Systemic Strategies Under Development for Gynecologic Cancers new

Interview with Jonathan A Ledermann, MD

Track 1: Biologic rationale for the use of PARP inhibitors in ovarian cancer (OC)
Track 2: Genetic alterations in OC and their sensitivity to PARP inhibition
Track 3: Incidence of homologous recombination deficiency (HRD) and identification of patients with OC who are most likely to benefit from PARP inhibitors
Track 4: Response to rucaparib in patients with BRCA-mutant and BRCA wild-type platinum-sensitive OC who have genomic loss of heterozygosity
Track 5: Efficacy and side-effect profiles of the PARP inhibitors olaparib, rucaparib and niraparib
Track 6: Activity of veliparib alone and in combination with chemotherapy for OC
Track 7: Results of the Phase III ENGOT-OV16/NOVA trial evaluating maintenance niraparib versus placebo for platinum-sensitive recurrent OC
Track 8: Study 19: Olaparib maintenance for platinum-sensitive, recurrent, serous OC
Track 9: Risk of myelodysplastic syndromes/acute myeloid leukemia in patients receiving PARP inhibitors
Track 10: Potential use of PARP inhibitors as adjuvant therapy for patients with BRCA-mutated OC
Track 11: Results of SOLO2: Significant improvement in progression-free survival with olaparib maintenance in patients with platinum-sensitive, relapsed, BRCA mutation-positive OC
Track 12: Comparison of olaparib versus niraparib as maintenance therapy for patients with BRCA-mutated OC
Track 13: Incorporation of rucaparib into the treatment algorithm for patients with BRCA mutation-positive, recurrent OC

Interview with Bradley J Monk, MD

Track 1: Management of platinum-sensitive, recurrent OC
Track 2: Choice of maintenance treatment with bevacizumab versus a PARP inhibitor for platinum-sensitive, relapsed OC in the second-line setting
Track 3: Activity of bevacizumab for platinum-resistant, recurrent OC
Track 4: Importance of genetic testing for all patients with OC
Track 5: Integration of bevacizumab into the clinical management of OC
Track 6: Role of neoadjuvant systemic therapy and intraperitoneal chemotherapy for patients with OC
Track 7: Mechanism of action, efficacy and tolerability of the novel antibody-drug conjugate mirvetuximab soravtansine
Track 8: Efficacy of bevacizumab for patients with endometrial cancer
Track 9: GOG 240: Improvement in overall survival with the addition of bevacizumab to chemotherapy in patients with recurrent, metastatic cervical cancer
Track 10: Potential adverse events associated with bevacizumab
Track 11: Investigation of listeria-based human papillomavirus (HPV) immunotherapy for advanced cervical cancer

Jonathan A Ledermann, MD
Professor of Medical Oncology
Clinical Director
University College London
Cancer Institute
Director, The Cancer Research UK
and UCL Cancer Trials Centre
London, United Kingdom
Bradley J Monk, MD
Division of Gynecologic Oncology
Arizona Oncology
(US Oncology Network)
University of Arizona College of Medicine - Phoenix
Creighton University School of Medicine at St Joseph’s Hospital
Phoenix, Arizona
Neil Love, MD
Research To Practice
Miami, Florida